Meeting
2015 Breast Cancer Symposium
TOX3 as a novel biomarker in luminal B breast cancer.
Authors
Jenny Jimmy Hong
Cedars-Sinai Medical Center, Los Angeles, CA
Jenny Jimmy Hong , Akop Seksenyan , Xiaopu Yuan , Beatrice Knudsen , William Audeh , Jonathan Kaye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Risk Assessment, Prevention, Early Detection, Screening, and Local/Regional Therapy
Track
Local/Regional Therapy,Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
Biology and Biomarkers
Citation
J Clin Oncol 33, 2015 (suppl 28S; abstr 130)
DOI
10.1200/jco.2015.33.28_suppl.130
Abstract #
130
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2013 Breast Cancer Symposium
21-gene recurrence score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor–positive (ER+) early-stage breast cancer (ESBC).
First Author: Jennifer B. Manders
Poster
2022 ASCO Annual Meeting
Estimating survival benefit of adjuvant chemotherapy in postmenopausal women with pT1-2N0 early-stage breast cancer and Oncotype DX recurrence score > 26: A National Cancer Database (NCDB) analysis.
First Author: Lifen Cao
Poster
2019 ASCO Annual Meeting
A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score.
First Author: Takeo Fujii